A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.
Article Details
- CitationCopy to clipboard
Brazel D, Arter Z, Nagasaka M
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.
Lung Cancer (Auckl). 2022 Nov 10;13:75-80. doi: 10.2147/LCTT.S383662. eCollection 2022.
- PubMed ID
- 36387582 [ View in PubMed]
- Abstract
KRAS(G12C) is one of the most common oncogenes in non-small cell lung cancer (NSCLC) and is associated with a poor prognosis. Historically, KRAS mutations have been difficult to target due to lack of binding sites and exceptionally high affinity for guanosine triphosphate/guanosine diphosphate (GTP/GDP). Recently, KRAS(G12C) selective inhibitors have shown promising results in Phase I/II studies. Here we discuss the mechanism of action, pharmacokinetic and pharmacodynamic properties, efficacy, and tolerability of adagrasib (MRTX849).
DrugBank Data that Cites this Article
- Drugs